Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EP300 | Q09472 | 2/20 | 0.50 |
| ▸ | TNF | P01375 | 7/20 | 0.48 |
| ▸ | FGFR1 | P11362 | 4/20 | 0.47 |
| ▸ | FGFR4 | P22455 | 4/20 | 0.47 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.47 |
| ▸ | ADCY5 | O95622 | 1/20 | 0.46 |
| ▸ | FDPS | P14324 | 1/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.45 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6045654 | 0.85 | EP300 (0.66) | EP300TNFFGFR1ADCY5ADORA2A | |
| SCHEMBL6045652 | 0.81 | EP300 (0.72) | EP300FGFR1ADCY5ADORA2A | |
| SCHEMBL6045566 | 0.81 | EP300 (0.72) | EP300FGFR1ADCY5ADORA2A | |
| SCHEMBL17078412 | 0.80 | HDAC1 (0.51) | EP300TNFP2RX7HDAC6 | |
| SCHEMBL28448960 | 0.80 | HSP90AB1 (0.48) | TNFHDAC6 | |
| SCHEMBL9534919 | 0.80 | P2RX7 (0.51) | FGFR1FGFR4P2RX7ADCY5FDPS | |
| SCHEMBL8982987 | 0.79 | ADORA2A (0.68) | FGFR1FGFR4P2RX7FDPSHDAC6 | |
| SCHEMBL31331791 | 0.79 | ADORA2A (0.68) | FGFR1FGFR4P2RX7FDPSHDAC6 | |
| SCHEMBL6045687 | 0.78 | EP300 (0.62) | EP300FGFR1ADCY5ADORA2A | |
| SCHEMBL10589823 | 0.77 | ADORA2A (0.61) | FGFR1FGFR4P2RX7FDPSHDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1313737-B1 | NOVEL GUANIDINO DERIVATIVES AS INHIBITORS OF CELL ADHESION | AVENTIS PHARMA GMBH (DE) | 2009-06-03 | — | — | EP | disclosed |
| US-7259159-B2 | Guanidino derivatives as inhibitors of cell adhesion | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-08-21 | — | — | US | disclosed |
| US-20030203896-A1 | Novel guanidino derivatives as inhibitors of cell adhesion | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2003-10-30 | — | — | US | disclosed |
| EP-1313737-A1 | NOVEL GUANIDINO DERIVATIVES AS INHIBITORS OF CELL ADHESION | Aventis Pharma Deutschland GmbH (DE) | 2003-05-28 | — | — | EP | disclosed |
| WO-2002010168-A1 | NOVEL GUANIDINO DERIVATIVES AS INHIBITORS OF CELL ADHESION | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2002-02-07 | — | — | WO | disclosed |
| EP-1176145-A1 | Novel guanidino derivatives as inhibitors of cell adhesion | Aventis Pharma Deutschland GmbH (DE) | 2002-01-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030203896-A1 | Novel guanidino derivatives as inhibitors of cell adhesion | ADGRF1, VCAM1, ADGRE5 | EP300 3163/4885TNF 1255/4885FGFR1 962/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.